We are a RNA therapeutics company using our proprietary, next-generation silicon stabilized hybrid lipid nanoparticles (sshNLP) to address unmet medical needs in the therapeutically neglected field of Genetic Skeletal Disorders. Built upon a decade of research and patented technological innovation, our BIO-COURIER® platform is changing the way therapeutic molecules target disease helping to make tomorrow’s medicines a reality.
Location: United Kingdom, England, Guildford
Member count: 11-50
Total raised: $17.5M
Founded date: 2008
Investors 2
| Date | Name | Website |
| - | Vickers Ve... | vickersven... |
| - | Clarendon ... | clarendon-... |
Funding Rounds 2
| Date | Series | Amount | Investors | Deal News |
| 27.11.2020 | - | $13.2M | Vickers Ve... | dealstreet... |
| 31.05.2018 | - | $4.3M | - | finsmes.co... |
Mentions in press and media 4
| Date | Title | Description | Category | Author | Source |
| 27.11.2020 | SG’s Vicke... | Premium Singapore-based ventu... | - | Mars W. Mo... | dealstreet... |
| 27.11.2020 | SG’s Vicke... | Singapore-based venture capita... | - | Mars W. Mo... | dealstreet... |
| 31.05.2018 | SiSaf Clos... | SiSaf, a Belfast and Guildford... | UK | - | finsmes.co... |
| 20.09.2016 | Singapore:... | Premium Vickers Venture Partn... | - | Shiwen Yap | dealstreet... |